search
Back to results

Effect of Thumbtack Needle on Ovarian Function of Women With Diminished Ovarian Reserve (DOR)

Primary Purpose

Diminished Ovarian Reserve

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
active thumbtack needle
sham thumbtack needle
Sponsored by
Huazhong University of Science and Technology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diminished Ovarian Reserve

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with age between 18 and 40 years;
  • Low ovarian reserve: AMH<1.1ng/ml; or AFC<7; or 10 U/L<FSH<25U/L or FSH/LH>3.6; or has a history of poor ovarian response, that is, in the last controlled hyperstimulation cycle, the number of retrieved oocytes<3. Any 2 of the above 4 conditions are met.
  • Sign informed consent voluntarily.

Exclusion Criteria:

  • Patient's chromosome is abnormal.
  • Patients with previous ovarian surgery because of such as ovarian teratoma or chocolate cyst and so on.
  • Patients with uncorrected endocrine disease, such as: Simple hyperthyroidism or hypothyroidism, hyperprolactinemia, insulin resistance, diabetes, adrenal diseases, etc.
  • Patients with definitively diagnosed autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, Sjogren's syndrome, Hashimoto's thyroiditis.
  • Patients with a history of cancer and has received radiotherapy or chemotherapy.
  • Patients had the treatment of acupuncture or thumbtack needle in recent 3 months.
  • Patients who take Chinese medicine decoction or granule during the treatment;
  • Patients unwilling to sign the informed consent of this study.

Sites / Locations

  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

treatment group

control group

Arm Description

Active thumbtack needle will be used for the treatment group

Sham thumbtack needle will be used for the control group

Outcomes

Primary Outcome Measures

Evaluating the change of serum AMH level
Assessing patients' serum level of AMH in ng/ml at baseline and immediately after treatment on the second day of menstruation.
Evaluating the change of the ovarian antral follicle count (AFC)
Counting the number of ovarian antral follicle count (AFC) on the second day of menstruation at baseline and immediately after treatment.

Secondary Outcome Measures

Evaluating the serum levels of sex hormones
Evaluating the serum levels of sex hormones on the second day of menstruation at baseline and immediately after treatment
Observing the sex hormones in follicular fluid collected from patients undergoing IVF/ICSI-ET cycle after treatment
Observing follicular fluid levels of sex hormones when patients undergoing IVF/ICSI -ET after the treatment.
Observing the level of transforming growth factor β (TGF β) in follicular fluid
Observing follicular fluid level of transforming growth factor β (TGF β) when patients undergoing IVF/ICSI -ET after the treatment.
Observing the level of tumor necrosis factor-α (TNF-α) in follicular fluid
Observing follicular fluid level of TNF-α when patients undergoing IVF/ICSI -ET after the treatment.
Observing the level of reactive oxygen species (ROS) in follicular fluid
Observing follicular fluid level of ROS when patients undergoing IVF/ICSI -ET after the treatment.
Observing the level of superoxide dismutase (SOD) in follicular fluid
Observing follicular fluid level of SOD when patients undergoing IVF/ICSI -ET after the treatment.
Observing the ovum morphology (MII ovum ratio) during IVF-ET after treatment
Observing the MII ovum ratio during IVF-ET after treatment
Observing the embryo status
Observing the grade I embryo ratio, blastocyst formation rate and high quality blastocyst ratio when patients undergoing IVF/ICSI-ET after the treatment
Observing the pregnancy status
Observing the biochemical, clinical and ongoing pregnancy rate
Blood corticotropin-releasing hormone (CRH) examination
Observing the level of blood corticotropin-releasing hormone (CRH) at baseline and immediately after treatment
Blood norepinephrine index examination
Observing the level of blood norepinephrine at baseline and immediately after treatment
Blood 5-hydroxytryptamine (5-HT) index examination
Observing the level of blood 5-hydroxytryptamine (5-HT) at baseline and immediately after treatment
Blood beta-aminobutyric acidne (DA) examination
Observing the level of blood beta-aminobutyric acidne (DA) at baseline and immediately after treatment
Blood beta-aminobutyric acid (GABA) examination
Observing the level of blood beta-aminobutyric acid (GABA) at baseline and immediately after treatment
Blood dopamine (DA) examination
Observing the level of blood dopamine (DA) at baseline and immediately after treatment
Blood neuro-endorphin (β-ET) examination
Observing the level of blood neuro-endorphin (β-ET) at baseline and immediately after treatment
Evaluation of anxiety status
Anxiety status will be assessed using Zung anxiety self-rating scale (Zung-SAS) at baseline and immediately after treatment.
Evaluation of depression status
Depression status will be assessed using Zung depression self-rating scale (Zung-SDS) at baseline and immediately after treatment.
Evaluation of quality of life
Quality of life will be assessed by SF-36 at baseline and immediately after treatment..
Evaluation of sleep state
Sleep status will be evaluated using Pittsburgh sleep quality index (PSQI) at baseline and immediately after treatment.

Full Information

First Posted
December 22, 2021
Last Updated
March 3, 2022
Sponsor
Huazhong University of Science and Technology
search

1. Study Identification

Unique Protocol Identification Number
NCT05277948
Brief Title
Effect of Thumbtack Needle on Ovarian Function of Women With Diminished Ovarian Reserve (DOR)
Official Title
Effect of Thumbtack Needle on Ovarian Function of Women With Diminished Ovarian Reserve (DOR): A Randomized Controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2021 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
October 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Huazhong University of Science and Technology

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Using a multi-center, large sample, randomized, controlled and blind clinical trial to evaluate the effect of thumbtack needle on ovarian function of patients with diminished ovarian reserve (DOR).
Detailed Description
Diminished ovarian reserve (DOR) is the precursor state of ovarian failure, and can cause the decline of women's reproductive function. Some studies have demonstrated that acupuncture can improve ovarian function. Thumbtack needle, as a kind of acupuncture, has been found effective in treating DOR in our clinic. In this trial, the investigators Using a multi-center, large sample, randomized, controlled and blind clinical trial to evaluate the effect of thumbtack needle on ovarian function of patients with diminished ovarian reserve (DOR). First, patients will be recruited according to the inclusion criteria and exclusion criteria. Second, baseline measurements (including ovarian reserve function, blood biochemical index, scores from the self-rating anxiety and depression scale, quality of life, sleep status) will be taken. Third, each patient will receive the treatment of thumbtack needle for a total of 2 menstrual cycles. Last, the above baseline measurements will be taken again as soon as the treatment is finished and outcome measures will be recorded after the treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diminished Ovarian Reserve

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
treatment group
Arm Type
Active Comparator
Arm Description
Active thumbtack needle will be used for the treatment group
Arm Title
control group
Arm Type
Sham Comparator
Arm Description
Sham thumbtack needle will be used for the control group
Intervention Type
Other
Intervention Name(s)
active thumbtack needle
Intervention Description
The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY). The patients were receive a treatment of 2 menstrual cycles
Intervention Type
Other
Intervention Name(s)
sham thumbtack needle
Intervention Description
The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile sham thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile sham electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY). The patients were receive a treatment of 2 menstrual cycles
Primary Outcome Measure Information:
Title
Evaluating the change of serum AMH level
Description
Assessing patients' serum level of AMH in ng/ml at baseline and immediately after treatment on the second day of menstruation.
Time Frame
0 week and up to 4 weeks
Title
Evaluating the change of the ovarian antral follicle count (AFC)
Description
Counting the number of ovarian antral follicle count (AFC) on the second day of menstruation at baseline and immediately after treatment.
Time Frame
0 week and up to 4 weeks
Secondary Outcome Measure Information:
Title
Evaluating the serum levels of sex hormones
Description
Evaluating the serum levels of sex hormones on the second day of menstruation at baseline and immediately after treatment
Time Frame
0 week and up to 4 weeks
Title
Observing the sex hormones in follicular fluid collected from patients undergoing IVF/ICSI-ET cycle after treatment
Description
Observing follicular fluid levels of sex hormones when patients undergoing IVF/ICSI -ET after the treatment.
Time Frame
through study completion, an average of 1 year
Title
Observing the level of transforming growth factor β (TGF β) in follicular fluid
Description
Observing follicular fluid level of transforming growth factor β (TGF β) when patients undergoing IVF/ICSI -ET after the treatment.
Time Frame
through study completion, an average of 1 year
Title
Observing the level of tumor necrosis factor-α (TNF-α) in follicular fluid
Description
Observing follicular fluid level of TNF-α when patients undergoing IVF/ICSI -ET after the treatment.
Time Frame
through study completion, an average of 1 year
Title
Observing the level of reactive oxygen species (ROS) in follicular fluid
Description
Observing follicular fluid level of ROS when patients undergoing IVF/ICSI -ET after the treatment.
Time Frame
through study completion, an average of 1 year
Title
Observing the level of superoxide dismutase (SOD) in follicular fluid
Description
Observing follicular fluid level of SOD when patients undergoing IVF/ICSI -ET after the treatment.
Time Frame
through study completion, an average of 1 year
Title
Observing the ovum morphology (MII ovum ratio) during IVF-ET after treatment
Description
Observing the MII ovum ratio during IVF-ET after treatment
Time Frame
through study completion, an average of 1 year
Title
Observing the embryo status
Description
Observing the grade I embryo ratio, blastocyst formation rate and high quality blastocyst ratio when patients undergoing IVF/ICSI-ET after the treatment
Time Frame
through study completion, an average of 1 year
Title
Observing the pregnancy status
Description
Observing the biochemical, clinical and ongoing pregnancy rate
Time Frame
through study completion, an average of 1 year
Title
Blood corticotropin-releasing hormone (CRH) examination
Description
Observing the level of blood corticotropin-releasing hormone (CRH) at baseline and immediately after treatment
Time Frame
0 week and up to 12 weeks
Title
Blood norepinephrine index examination
Description
Observing the level of blood norepinephrine at baseline and immediately after treatment
Time Frame
0 week and up to 12 weeks
Title
Blood 5-hydroxytryptamine (5-HT) index examination
Description
Observing the level of blood 5-hydroxytryptamine (5-HT) at baseline and immediately after treatment
Time Frame
0 week and up to 12 weeks
Title
Blood beta-aminobutyric acidne (DA) examination
Description
Observing the level of blood beta-aminobutyric acidne (DA) at baseline and immediately after treatment
Time Frame
0 week and up to 12 weeks
Title
Blood beta-aminobutyric acid (GABA) examination
Description
Observing the level of blood beta-aminobutyric acid (GABA) at baseline and immediately after treatment
Time Frame
0 week and up to 12 weeks
Title
Blood dopamine (DA) examination
Description
Observing the level of blood dopamine (DA) at baseline and immediately after treatment
Time Frame
0 week and up to 12 weeks
Title
Blood neuro-endorphin (β-ET) examination
Description
Observing the level of blood neuro-endorphin (β-ET) at baseline and immediately after treatment
Time Frame
0 week and up to 12 weeks
Title
Evaluation of anxiety status
Description
Anxiety status will be assessed using Zung anxiety self-rating scale (Zung-SAS) at baseline and immediately after treatment.
Time Frame
0 week and up to 4 weeks
Title
Evaluation of depression status
Description
Depression status will be assessed using Zung depression self-rating scale (Zung-SDS) at baseline and immediately after treatment.
Time Frame
0 week and up to 4 weeks
Title
Evaluation of quality of life
Description
Quality of life will be assessed by SF-36 at baseline and immediately after treatment..
Time Frame
0 week and up to 4 weeks
Title
Evaluation of sleep state
Description
Sleep status will be evaluated using Pittsburgh sleep quality index (PSQI) at baseline and immediately after treatment.
Time Frame
0 week and up to 4 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with age between 18 and 40 years; Low ovarian reserve: AMH<1.1ng/ml; or AFC<7; or 10 U/L<FSH<25U/L or FSH/LH>3.6; or has a history of poor ovarian response, that is, in the last controlled hyperstimulation cycle, the number of retrieved oocytes<3. Any 2 of the above 4 conditions are met. Sign informed consent voluntarily. Exclusion Criteria: Patient's chromosome is abnormal. Patients with previous ovarian surgery because of such as ovarian teratoma or chocolate cyst and so on. Patients with uncorrected endocrine disease, such as: Simple hyperthyroidism or hypothyroidism, hyperprolactinemia, insulin resistance, diabetes, adrenal diseases, etc. Patients with definitively diagnosed autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, Sjogren's syndrome, Hashimoto's thyroiditis. Patients with a history of cancer and has received radiotherapy or chemotherapy. Patients had the treatment of acupuncture or thumbtack needle in recent 3 months. Patients who take Chinese medicine decoction or granule during the treatment; Patients unwilling to sign the informed consent of this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dongmei Huang
Phone
86-27-83663275
Email
hdmjcr@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hanwang Zhang
Organizational Affiliation
Huazhong University of Science Tech
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430030
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dongmei a Huang
Phone
86 27 83663275
Email
hdmjcr@qq.com

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
we use the Clinical Trial Management Public Platform to manage and share our date
IPD Sharing Time Frame
January, 2027, for 1 year
IPD Sharing Access Criteria
only for research

Learn more about this trial

Effect of Thumbtack Needle on Ovarian Function of Women With Diminished Ovarian Reserve (DOR)

We'll reach out to this number within 24 hrs